Dashboard
Manage Tickers

REPLReplimune Group, Inc.

Nasdaq replimune.com


$ 8.10 $ 0.02 (0.25 %)    

Friday, 05-Jul-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 8.11
$ 8.10
$ 0.00 x 0
$ 0.00 x 0
$ 7.88 - $ 8.11
$ 4.92 - $ 22.21
335,957
na
539.88M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-16-2024 03-31-2024 10-K
2 02-08-2024 12-31-2023 10-Q
3 11-07-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-18-2023 03-31-2023 10-K
6 02-09-2023 12-31-2022 10-Q
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-19-2022 03-31-2022 10-K
10 02-03-2022 12-31-2021 10-Q
11 11-04-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-20-2021 03-31-2021 10-K
14 02-04-2021 12-31-2020 10-Q
15 11-05-2020 09-30-2020 10-Q
16 08-07-2020 06-30-2020 10-Q
17 06-03-2020 03-31-2020 10-K
18 02-13-2020 12-31-2019 10-Q
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 06-28-2019 03-31-2019 10-K
22 02-14-2019 12-31-2018 10-Q
23 11-14-2018 09-30-2018 10-Q
24 08-30-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

replimune-announces-private-placement-financing-with-an-institutional-investor-for-gross-proceeds-of-100m
Replimune Announces Private Placement Fina...
06/13/2024 12:37:14

barclays-maintains-overweight-on-replimune-group-raises-price-target-to-17
Barclays Maintains Overweight on Replimune...
06/07/2024 18:04:31

Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $13...

vail-resorts-posts-downbeat-q3-results-joins-concrete-pumping-docusign-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Vail Resorts Posts Downbeat Q3 Results, Jo...
06/07/2024 12:22:35

hc-wainwright--co-maintains-buy-on-replimune-group-raises-price-target-to-17
HC Wainwright & Co. Maintains Buy on Repli...
06/07/2024 11:15:30

HC Wainwright & Co. analyst Robert Burns maintains Replimune Group (NASDAQ:REPL) with a Buy and raises the price target ...

sp-500-edges-lower-j-m-smucker-shares-surge-following-earnings-beat
S&P 500 Edges Lower; J. M. Smucker Shares ...
06/06/2024 18:45:57

why-g-iii-apparel-shares-are-trading-lower-by-13-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why G-III Apparel Shares Are Trading Lower...
06/06/2024 17:39:18

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
06/06/2024 16:31:11

crude-oil-jumps-2-lululemon-posts-upbeat-earnings
Crude Oil Jumps 2%; Lululemon Posts Upbeat...
06/06/2024 16:22:51

why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday
Why Is Mid-Cap Cancer-Focused Replimune St...
06/06/2024 16:16:20

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rat...

jm-smucker-posts-upbeat-earnings-joins-toro-company-united-natural-foods-semtech-and-other-big-stocks-moving-higher-on-thursday
J.M. Smucker Posts Upbeat Earnings, Joins ...
06/06/2024 14:44:41

replimune-says-topline-results-from--primary-analysis-of-the-ignyte-clinical-trial-of-rp1-plus-nivolumab-in-anti-pd1-failed-melanoma-primary-endpoint-data-shows-12-month-overall-response-rate-of-336
Replimune Says Topline Results From Prima...
06/06/2024 11:31:31

replimune-to-present-data-from-rp1-and-rp2-clinical-programs-at-the-2024-asco-annual-meeting-12-month-results-from-the-ignyte-clinical-trial-of-rp1-plus-nivolumab-in-anti-pd-1-failed-melanoma-demonstrate-an-overall-response-rate-of-327-and-duration-of-response-consistent-with-the-previously-reported-6-month-data-from-ignyte-trial
Replimune To Present Data From RP1 And RP2...
06/03/2024 12:26:50

-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma dem...

replimune-group-inc-expects-enrollment-of-first-patients-in-phase-3-confirmatory-trial-of-rp1-in-advanced-melanoma-in-2h-2024
Replimune Group Inc. Expects Enrollment Of...
05/16/2024 12:11:54

https://www.benzinga.com/secfilings/24/05/38870181/replimune-group-inc-general-corporate-statement-form8

replimune-group-presented-the-interim-results-from-the-artacus-clinical-trial-of-rp1-monotherapy-in-solid-organ-and-hematopoietic-cell-transplant-recipients-with-skin-cancers-at-aacr-2024
Replimune Group Presented The Interim Resu...
04/08/2024 06:21:02

In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent...

replimune-appoints-sushil-patel-to-ceo-succeeding-philip-astley-sparke-effective-april-1-2024-mr-astley-sparke-will-transition-from-his-current-role-as-ceo-to-executive-chairman-of-the-board-of-director
Replimune Appoints Sushil Patel To CEO Suc...
03/26/2024 11:35:24

replimune-group-q3-earnings-insights
Replimune Group: Q3 Earnings Insights
02/08/2024 13:10:05

replimune-group-q3-eps-077-beats-093-estimate
Replimune Group Q3 EPS $(0.77) Beats $(0.9...
02/08/2024 13:03:56

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.9...

barclays-maintains-overweight-rating-for-replimune-group-heres-what-you-need-to-know
Barclays Maintains Overweight Rating for R...
12/06/2023 17:00:28

barclays-maintains-overweight-on-replimune-group-lowers-price-target-to-13
Barclays Maintains Overweight on Replimune...
12/06/2023 11:36:17

Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $50...

crude-oil-moves-lower-autozone-profit-tops-views
Crude Oil Moves Lower; AutoZone Profit Top...
12/05/2023 19:27:49

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)